Business Description
TG Therapeutics is a US-based biopharmaceutical company that develops and sells treatments for diseases driven by abnormal B-cell activity. Its flagship product, BRIUMVI, is an approved therapy for adults living with relapsing forms of multiple sclerosis. The company also has several drugs in development, including treatments targeting multiple sclerosis and certain blood-related conditions, and works alongside a number of pharmaceutical partners across global markets.
